Oisin Biotechnologies Revenue and Competitors
Estimated Revenue & Valuation
- Oisin Biotechnologies's estimated annual revenue is currently $1.6M per year.
- Oisin Biotechnologies's estimated revenue per employee is $77,500
- Oisin Biotechnologies's total funding is $7.1M.
Employee Data
- Oisin Biotechnologies has 20 Employees.
- Oisin Biotechnologies grew their employee count by -9% last year.
Oisin Biotechnologies's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder and Scientific Advisor | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Operating Officer | Reveal Email/Phone |
4 | Chief Business Officer | Reveal Email/Phone |
5 | Co-founder & Chief Science Officer | Reveal Email/Phone |
6 | Lead Scientist | Reveal Email/Phone |
7 | Executive Chairman and Co-Founder | Reveal Email/Phone |
Oisin Biotechnologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Oisin Biotechnologies?
Oisin Biotechnologies is a longevity therapeutics platform company focused on creating genetic medicines to combat a variety of age related diseases. When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function. Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases. Oisín Biotechnologies is developing a highly precise, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.
keywords:N/A$7.1M
Total Funding
20
Number of Employees
$1.6M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oisin Biotechnologies News
Merck & Co., Inc. Oisin Biotechnologies; Pfizer Inc. T.A. Sciences, Inc. Unity Biotechnology, Inc. Avenue Basic Plan | Library Access | 1 Year...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.8M | 20 | -23% | N/A |
#2 | $1.4M | 20 | 11% | $18.5M |
#3 | $1.4M | 20 | -9% | $12.5M |
#4 | $2M | 20 | N/A | N/A |
#5 | $2M | 20 | N/A | N/A |